Altium Capital Management LLC Takes $2.86 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Altium Capital Management LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 95,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,860,000.

Other institutional investors also recently bought and sold shares of the company. HighTower Advisors LLC lifted its position in TG Therapeutics by 19.6% in the third quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 2,053 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of TG Therapeutics by 12.7% in the third quarter. Wellington Management Group LLP now owns 73,320 shares of the biopharmaceutical company’s stock worth $1,715,000 after buying an additional 8,249 shares during the period. Barclays PLC boosted its position in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in TG Therapeutics in the 3rd quarter worth $1,039,000. Finally, Synovus Financial Corp purchased a new position in shares of TG Therapeutics in the third quarter valued at about $465,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Up 0.3 %

TGTX stock opened at $38.32 on Friday. The company has a market capitalization of $6.02 billion, a price-to-earnings ratio of -383.16 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business’s 50 day moving average price is $36.20 and its two-hundred day moving average price is $31.74. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TGTX shares. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.